ID   A2780-CBDCA-R
AC   CVCL_ZE22
SY   CBDCA-R-A2780
DR   cancercelllines; CVCL_ZE22
DR   Wikidata; Q98125441
RX   PubMed=30894224;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Paraplatin).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=30894224; DOI=10.1186/s40659-019-0220-0;
RA   Viscarra T., Buchegger K., Jofre I.A., Riquelme I., Zanella L.,
RA   Abanto Marin M., Parker A.C., Piccolo S.R., Roa J.C., Ili C.G.,
RA   Brebi P.;
RT   "Functional and transcriptomic characterization of
RT   carboplatin-resistant A2780 ovarian cancer cell line.";
RL   Biol. Res. 52:13.1-13.13(2019).
//